Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

Launched by VALL D'HEBRON INSTITUTE OF ONCOLOGY · Jun 20, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to improve treatment for patients with triple-negative breast cancer (TNBC), a type of breast cancer that does not respond to certain hormone therapies. The study will include patients with stage II-III TNBC who are about to start chemotherapy, and some may also receive a treatment called an immune checkpoint inhibitor, which helps the immune system fight cancer. Researchers will analyze samples from different tissues to find biological markers that can predict how well patients will respond to these treatments. The goal is to create a helpful tool for doctors to make better treatment decisions for their patients.

To participate, patients need to be at least 18 years old and have a confirmed diagnosis of stage II-III TNBC that has not spread to other parts of the body. This trial is currently recruiting participants, and both men and women are welcome. If you join, you can expect to provide various tissue samples and undergo assessments to help researchers understand how these treatments work and who might benefit the most from them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically documented TNBC (negative human epidermal growth factor receptor 2 \[HER2\], estrogen receptor \[ER\], and progesterone receptor \[PgR\] status)
• • Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment
• • Patient is a candidate to receive NACT with or without ICI as assessed by the investigator
• • Patient is ≥ 18 years old at the time of consent to participate in this trial
• Exclusion Criteria:
• • Metastatic disease on imaging (stage 4)